Atıf Sayısı
1
Görüntüleme
102
İndirme
5
Yüksek mobilite grup kutusu 1 (HMGB1) histon olmayan DNA proteini olup, kısaca DAMP olarak ifade edilen (Damage-associated molecular pattern) tehlike sinyali veya alarmı olarak görev yapar. Hasarlanmış veya kanserli hücrelerden salınan HMGB1, gelişmiş glikasyon son ürünleri için reseptör (RAGE) ve Toll benzeri reseptörlerine (TLRs) bağlanarak mitojenle aktive olan kinaz (MAPK)’ları aktive ederek hücre içi etkilerini oluşturur. HMGB1 kanser ilaçlarına karşı gelişen dirençte önemli rol oynar. Aynı zamanda, yumuşak doku kanserlerine karşı kullanılan ilaçlardan biri olan adriyamisinin (ADR) neden olduğu kalp yetmezliğinin gelişiminde de önemli rol oynağına dair kanıtlar mevcuttur. Dolayısıyla HMGB1 kanser tedavisinde ilaçlara karşı gelişen direncin ve/veya ilacın toksik etkisine karşı iyi bir terapötik ajan adayıdır. Bu derlemenin amacı, HMGB1 ile kanser ve tedavisinde kullanılan bir ilaç olan ADR arasındaki ilişkiyi açıklamaktır.
High-mobility group box 1 (HMGB1) is a non-histon DNA protein and serves as a DAMP (Damage-associated molecular pattern) danger signal or alarm. HMGB1, released from damaged or cancerous cells, creates cellular effects by activating kinase (MAPKs) activated by connecting to receptors (RAGE) and Toll-like receptors (TLRs) for advanced glycation final products. HMGB1 plays an important role in developing resistance to cancer drugs. At the same time, there are evidence that adriamycin (ADR), one of the drugs used against soft tissue cancers, also plays an important role in the development of heart failure. HMGB1 is therefore a good therapeutic candidate for the development of resistance to drugs and/or to the toxic effects of the drug in the treatment of cancer. The purpose of this collection is to explain the relationship between HMGB1 and ADR, a drug used in cancer and treatment.
High mobility group box-1 (HMGB1), one of nonhiston protein, plays role as danger signals, and alarming shortly named as DAMP. HMGB1 released from damaged and cancer cells triggers mitogen activated kinases (MAPK) to act intracellular effect by binding the receptor for advanced glycation end products (RAGE) and toll like receptor (TLR). HMGB1 is essential to develop resistant against anticancer drugs. In addition, there is evidence that HMGB1 participate in developing to heart failure-induced by Adriamycin, one of anticancer drug against for solid cancer. Therefore, HMGB1 could be a good candidate for drug-resistant against to cancer and/or anticancer drug toxicity. The aim of the present review is to explain the relationship between HMBG1, cancer and Adriamycin used for cancer’s treatment.
Alan : Fen Bilimleri ve Matematik
Dergi Türü : Ulusal
Makale Detay 
Atıf Yapanlar
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Bu Sayfayı Yazdırın
Paylaş
Mendeley
